Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2018. The document serves as a transaction notification regarding a sale of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is limited to a specific insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Volume | 65,000 shares |
| Price per Share | £14.6967 |
| Transaction Date | May 15, 2018 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It solely discloses a reduction in shareholding by a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies related to the company's business outlook. It is a regulatory disclosure of an insider trade.
Important Facts for Investors
- Insider Sale: Mr. P Thomson, President of Global Affairs, sold 65,000 ordinary shares.
- Transaction Value: The sale occurred at a price of £14.6967 per share.
- Regulatory Nature: This is a mandatory disclosure under Rule 13a-16/15d-16 and does not reflect broader corporate performance.
- No Financial Data: Investors should refer to the company's Form 20-F or interim reports for revenue, profit, and liquidity data.